Literature DB >> 1365667

Effects of chronic nicotine and haloperidol administration on muscarinic receptor-mediated phosphoinositide turnover in rat brain slices.

R Li1, L L Wing, D G Kirch, R J Wyatt, D M Chuang.   

Abstract

Muscarinic receptor-mediated phosphoinositide (PI) turnover in rat brain slices was assessed after chronic administration of nicotine (12 mg/kg/day) or haloperidol decanoate (1.5 mg/kg/day), either alone or in combination, for 6 weeks. Nicotine alone did not significantly alter carbachol-induced inositol monophosphate (IP1) accumulation in the frontal cortex, but did result in a significant increase in the hippocampus, and in a decrease in the striatum. Haloperidol alone attenuated carbachol-stimulated IP1 accumulation in all three brain regions. Chronic treatment with combined nicotine and haloperidol resulted in no significant change in carbachol-sensitive IP1 accumulation in either the frontal cortex or hippocampus but did result in a decrease in the striatum. The results suggest significant cross-talk between cholinergic and dopaminergic systems in affecting PI metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365667     DOI: 10.1007/bf02245510

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.

Authors:  C Prasad; S A Spahn; H Ikegami
Journal:  Biochem Biophys Res Commun       Date:  1989-02-28       Impact factor: 3.575

Review 2.  Inositol lipids and signal transduction in the nervous system: an update.

Authors:  S K Fisher; A M Heacock; B W Agranoff
Journal:  J Neurochem       Date:  1992-01       Impact factor: 5.372

Review 3.  Neurotransmitter receptors and phosphoinositide turnover.

Authors:  D M Chuang
Journal:  Annu Rev Pharmacol Toxicol       Date:  1989       Impact factor: 13.820

4.  Smoking and tardive dyskinesia.

Authors:  R L Binder; H Kazamatsuri; T Nishimura; D E McNiel
Journal:  Biol Psychiatry       Date:  1987-10       Impact factor: 13.382

Review 5.  Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia.

Authors:  D G Kirch; A M Alho; R J Wyatt
Journal:  Cell Mol Neurobiol       Date:  1988-09       Impact factor: 5.046

Review 6.  The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory.

Authors:  M W Decker; J L McGaugh
Journal:  Synapse       Date:  1991-02       Impact factor: 2.562

7.  Effect of nicotine pretreatment on striatal dopaminergic system in rats.

Authors:  Y K Fung; Y S Lau
Journal:  Pharmacol Biochem Behav       Date:  1989-01       Impact factor: 3.533

8.  Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors.

Authors:  D G Kirch; T R Taylor; I Creese; S X Xu; R J Wyatt
Journal:  J Pharm Pharmacol       Date:  1992-02       Impact factor: 3.765

9.  Cholinergic stimulation of inositol phosphate formation in bovine adrenal chromaffin cells: distinct nicotinic and muscarinic mechanisms.

Authors:  D A Eberhard; R W Holz
Journal:  J Neurochem       Date:  1987-11       Impact factor: 5.372

10.  Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain.

Authors:  D G Kirch; G A Gerhardt; R C Shelton; R Freedman; R J Wyatt
Journal:  Clin Neuropharmacol       Date:  1987-08       Impact factor: 1.592

View more
  2 in total

Review 1.  Neurotransmitter receptor expression and activity during neuronal differentiation of embryonal carcinoma and stem cells: from basic research towards clinical applications.

Authors:  H Ulrich; P Majumder
Journal:  Cell Prolif       Date:  2006-08       Impact factor: 6.831

2.  Effect of chronic haloperidol treatment on dopamine-induced inositol phosphate formation in rat brain slices.

Authors:  R Li; D M Chuang; R J Wyatt; D G Kirch
Journal:  Neurochem Res       Date:  1994-06       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.